Weekly Spotlight - 31.10.24

In the News

Webinar Series on Systemic Sclerosis Management and Guidelines

The webinar series, led by Professor Christopher Denton, explores the 2024 BSR guidelines for systemic sclerosis management. It covers SSc assessment, classification, and treatment, focusing on cardiorespiratory and vasculopathy complications. The series aims to enhance understanding and implementation of these guidelines in clinical practice, fostering a supportive community.

CAL101 Shows Promise in Treating Fibrosis in Early Trials

CAL101, developed by Calluna Pharma, is a promising treatment for fibrosis in scleroderma, showing safety and tolerability in Phase 1 trials. Targeting the S100A4 protein, it aims to prevent fibrosis. Encouraged by these results, Calluna plans Phase 2 trials in 2025, offering hope for fibrotic diseases.

Men's Health in Scleroderma: Addressing Gender Disparities in Outcomes

The study highlights that men with scleroderma-associated pulmonary hypertension face worse outcomes than women, with more cardiovascular events and reduced survival. The absence of protective estrogen and testosterone's negative effects may contribute. Gender-specific management, including early cardiac assessments and hormonal therapies, is recommended to improve prognosis.

Morphea: Understanding and Treating Localised Scleroderma Today

The article discusses the rising incidence of morphea, a form of localized scleroderma, and reviews current treatment options. Despite ongoing research, no highly specific therapies exist yet. However, new studies offer hope for future treatments that could better address both inflammation and fibrosis, providing optimism for patients and their families.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!